SAVE-MORE
Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early Management Of seveRE respiratory failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial Brief Description SAVE-MORE is a double-blind randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by
ACTIVATE-II
Completed study Official Study Title A randomized clinical trial for enhanced trained immune responses through Bacillus Calmette-Guérin vaccination to prevent infections by COVID-19 Brief Description ACTIVATE-II is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination exists in
ACHIEVE
Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory
SAVE
Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker
ESCAPE
Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous
INCREDIBLE-ME
Ongoing study Official Study Title Gut-derived INCREtin hormones in the pathophysiology of Type 1 DiaBetes MeLlitus; Effect of Metformin treatment (the INCREDIBLE-ME trial) Brief Description INCREDIBLE-ME is a randomized clinical trial aiming to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion.